Literature DB >> 18937232

Multiple primary tumors in men with breast cancer diagnoses: a SEER database review.

Jessica A Wernberg1, Johnny Yap, Christine Murekeyisoni, Terry Mashtare, Gregory E Wilding, Swati A Kulkarni.   

Abstract

BACKGROUND: Male breast cancer (MBC) comprises 1% of all breast cancers and less than 1% of cancer cases in men. After a diagnosis of MBC, men are at risk of developing a second primary cancer, particularly a second primary breast cancer. The objective of this study is to analyze the characteristics of the population of men diagnosed with a second malignancy, specifically a second MBC.
METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database, 4,873 male patients diagnosed with invasive or in situ breast cancer from 1973 to 2004 were identified and data from patients who developed a second MBC were reviewed. Additional non-breast primary cancer diagnoses were also recorded.
RESULTS: A review of 4,966 records corresponding to 4,873 patients revealed 4,462 invasive and 504 in situ breast cancer events. Of the 4,873 patients, 93 (1.9%) were identified with a second MBC. Among the 4,873 patients with MBC, 1,001 (21%) have other non-breast primary cancer diagnoses recorded in the SEER registry.
CONCLUSIONS: Although MBC is uncommon, these patients are at risk of a contralateral breast cancer and second primary non-breast cancers. Our findings support that men with breast cancer would benefit from continued long-term surveillance for breast cancer and appropriate screening for non-breast cancers.

Entities:  

Mesh:

Year:  2009        PMID: 18937232     DOI: 10.1002/jso.21153

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

1.  Lack of association between cyclin-dependent kinase inhibitor 1B rs2066827 polymorphism and breast cancer susceptibility.

Authors:  Zhong-Ming Jia; Yan Liu; Shou-Yong Cui
Journal:  Tumour Biol       Date:  2014-02-13

2.  Multidisciplinary meeting on male breast cancer: summary and research recommendations.

Authors:  Larissa A Korde; Jo Anne Zujewski; Leah Kamin; Sharon Giordano; Susan Domchek; William F Anderson; John M S Bartlett; Karen Gelmon; Zeina Nahleh; Jonas Bergh; Bruno Cutuli; Giancarlo Pruneri; Worta McCaskill-Stevens; Julie Gralow; Gabriel Hortobagyi; Fatima Cardoso
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

3.  Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers.

Authors:  Patricia A Cronin; Anya Romanoff; Emily C Zabor; Michelle Stempel; Anne Eaton; Lillian M Smyth; Alice Y Ho; Monica Morrow; Mahmoud El-Tamer; Mary L Gemignani
Journal:  Ann Surg Oncol       Date:  2018-10-08       Impact factor: 5.344

4.  Risk of Second Non-Breast Primary Cancer in Male and Female Breast Cancer Patients: A Population-Based Cohort Study.

Authors:  Man-Hsin Hung; Chia-Jen Liu; Chung-Jen Teng; Yu-Wen Hu; Chiu-Mei Yeh; San-Chi Chen; Sheng-Hsuan Chien; Yi-Ping Hung; Cheng-Che Shen; Tzeng-Ji Chen; Cheng-Hwai Tzeng; Chun-Yu Liu
Journal:  PLoS One       Date:  2016-02-19       Impact factor: 3.240

Review 5.  Male Breast Cancer: From Molecular Genetics to Clinical Management.

Authors:  Matilde Pensabene; Claudia Von Arx; Michelino De Laurentiis
Journal:  Cancers (Basel)       Date:  2022-04-15       Impact factor: 6.575

6.  A Clinicopathological Evaluation of Male Patients with Breast Cancer.

Authors:  Enver Ilhan; Bakir Bati; Ali Alemdar; Ali Coskun; Arsenal Sezgin; Mehmet Yildirim; Omer Engin; Mete Purten
Journal:  Breast Care (Basel)       Date:  2009-10-01       Impact factor: 2.860

7.  Male breast cancer: 37-year data study at a single experience center in Turkey.

Authors:  Fatih Selcukbiricik; Deniz Tural; Fatih Aydoğan; Nuran Beşe; Evin Büyükünal; Süheyla Serdengeçti
Journal:  J Breast Cancer       Date:  2013-03-31       Impact factor: 3.588

8.  Correlation of the BACH1 Pro919Ser polymorphism with breast cancer risk: A literature-based meta-analysis and meta-regression analysis.

Authors:  Jing Shi; Jianhua Tong; Shuang Cai; Xiujuan Qu; Yunpeng Liu
Journal:  Exp Ther Med       Date:  2013-06-07       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.